IPP Bureau
M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness
By IPP Bureau - February 02, 2025
Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages
Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
By IPP Bureau - February 01, 2025
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
BMS receives positive CHMP opinion for Opdivo plus Yervoy as a first-line treatment option for advanced hepatocellular carcinoma
By IPP Bureau - February 01, 2025
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
MicrobioTx introduces innovative probiotic range for personalized wellness
By IPP Bureau - February 01, 2025
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
Roche receives FDA approval for the first companion diagnostic to identify patients ultralow metastatic breast cancer
By IPP Bureau - February 01, 2025
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
By IPP Bureau - February 01, 2025
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Jubilant Ingrevia commissions new cGMP facility for supplying Niacinamide to global clients
By IPP Bureau - January 31, 2025
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
NATCO announces approval of its ANDA for Everolimus tablets for Oral Suspension
By IPP Bureau - January 31, 2025
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
Granules strengthens ADHD portfolio with FDA approval for Lisdexamfetamine Dimesylate capsules
By IPP Bureau - January 31, 2025
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
Strides reports 14.6% growth in Q3 FY25 revenue
By IPP Bureau - January 31, 2025
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Biocon posts Q3 FY25 PAT at Rs. 25 Cr
By IPP Bureau - January 31, 2025
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Biocon’s S&P Global ESG Score improves to 69 for 2024
By IPP Bureau - January 30, 2025
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Piramal Pharma Q3 FY25 revenue up 13%
By IPP Bureau - January 30, 2025
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Roche appoints Wafaa Mamilli as Chief Digital Technology Officer
By IPP Bureau - January 30, 2025
Mamilli last held the role of Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health at Zoetis
Enhertu approved in US for breast cancer post more endocrine therapies
By IPP Bureau - January 30, 2025
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
